Subscribe to Science Friday
A new mRNA flu vaccine made by Moderna was approved by the FDA in August, and is currently available for people aged 50 and over. The promise of an mRNA vaccine for flu is that it can be spun up more quickly than a traditional vaccine, meaning it could better match the flu strain that’s circulating.
Is that what happened this year? How are the side effects? And how has dysfunction at the health agencies impacted rollout? Flora discusses these questions and more with vaccine researcher Anna Durbin.
Donate To Science Friday
Invest in quality science journalism by making a donation to Science Friday.
Segment Guests
Anna Durbin
Dr. Anna Durbin is a vaccine researcher, professor of international health, and director of the Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health.
Segment Transcript
The transcript is being processed. It will be available 2-3 days after this story’s publication date.
Meet the Producers and Host
About Flora Lichtman
Flora Lichtman is a host of Science Friday. In a previous life, she lived on a research ship where apertivi were served on the top deck, hoisted there via pulley by the ship’s chef.
About Shoshannah Buxbaum
Shoshannah Buxbaum is a producer for Science Friday. She’s particularly drawn to stories about health, psychology, and the environment. She’s a proud New Jersey native and will happily share her opinions on why the state is deserving of a little more love.